Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.
NCT01289028
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
125
Enrollment
INDUSTRY
Sponsor class
Conditions
Gastrointestinal Stromal Tumors
Interventions
DRUG:
Nilotinib
Sponsor
Novartis Pharmaceuticals